NCOA3 and breast cancer: Indeed, overexpression of the co-activator AIB1 correlates with resistance to tamoxifen in breast cancer patients and in the EGFR/HER2/MAPK-dependent phosphorylation, and it has been proposed to mediate tamoxifen resistance in HER2 overexpressing MCF-7 cells [101].